阿斯利康:临床研究显示靶向抗癌药泰瑞沙将无进展生存期延长3年以上
子墨764
发表于 2024-6-3 09:32:03
1174
0
0
经盲法独立中央审查(BICR)评估的结果显示,与安慰剂相比,泰瑞沙可将疾病进展或死亡风险降低84%。接受泰瑞沙治疗的患者的中位PFS为39.1个月,而接受安慰剂治疗的患者的中位PFS为5.6个月。
总生存期(OS)数据显示泰瑞沙的有利趋势,尽管数据在本分析时尚不成熟。该试验将将继续评估次要终点OS。
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.